Top 10 HEOR Companies in Immunology and Autoimmune Diseases

The growing complexity of immunology and autoimmune diseases ranging from rheumatoid arthritis and lupus to multiple sclerosis and psoriasis has made Health Economics and Outcomes Research (HEOR) indispensable. As biopharmaceutical companies seek market access and payer approval for high-cost therapies, HEOR evidence forms the backbone of value demonstration strategies. Below is a curated list of the Top 10 HEOR Companies in Immunology and Autoimmune Diseases that are shaping the landscape of evidence generation and health technology assessment (HTA).

1. DelveInsight

DelveInsight stands out as a premier HEOR and market intelligence partner for pharmaceutical and biotech companies operating in immunology and autoimmune diseases. With deep domain expertise spanning rheumatology, dermatology, gastroenterology, and neurology, DelveInsight delivers robust economic modeling, cost-effectiveness analyses, and real-world evidence (RWE) strategies tailored to specific therapy areas.

Their HEOR services include budget impact models (BIM), patient-reported outcomes (PRO) frameworks, systematic literature reviews (SLR), and HTA submission support across major markets including the US, EU5, and Japan. DelveInsight's integrated approach — combining clinical, epidemiological, and payer insights helps clients navigate the evolving reimbursement landscape for biologics and advanced therapies in autoimmune conditions.

Whether you're seeking early-stage value frameworks or late-stage global value dossiers (GVDs), DelveInsight remains a trusted partner from pipeline to launch.

2. ICON plc

ICON plc is a global CRO and outcomes research organization offering comprehensive HEOR support. Their immunology practice focuses on systematic reviews, network meta-analyses (NMA), and payer evidence strategies for biologic therapies targeting autoimmune conditions like Crohn's disease, psoriatic arthritis, and ankylosing spondylitis.

3. Parexel International

Parexel's HEOR and market access division provides integrated solutions including epidemiological modeling, comparative effectiveness research, and HTA support. Their autoimmune disease portfolio covers a wide spectrum of conditions, helping manufacturers build compelling evidence for regulatory and reimbursement bodies.

4. Evidera (a PPD company)

Evidera is a global leader in real-world evidence and outcomes research. In immunology, they specialize in patient-centered outcomes measurement, observational studies, and meta-analytic research to support market access of novel therapies for diseases like systemic lupus erythematosus (SLE) and inflammatory bowel disease (IBD).

5. IQVIA

IQVIA combines real-world data assets with advanced analytics and HEOR expertise. Their immunology capabilities extend from epidemiology and burden-of-disease studies to regulatory-grade RWE generation, supporting payer negotiations and HTA submissions globally.

6. Cerner Enviza (formerly Kantar Health)

Cerner Enviza brings deep expertise in patient survey research, burden-of-illness studies, and treatment pattern analysis. In the autoimmune space, they help companies understand unmet needs, treatment gaps, and quality-of-life (QoL) impacts that are critical for formulary positioning.

7. Mtech Access

Mtech Access is a specialist health economics consultancy known for its excellence in economic modeling and HTA consultancy in the UK and EU. Their work in rheumatology and dermatology supports NICE, SMC, and other HTA body submissions for biologic and small-molecule immunology therapies.

8. Broadstreet Health Economics & Outcomes Research

Broadstreet offers specialized HEOR consulting with a focus on rare and chronic autoimmune diseases. Their services include indirect treatment comparisons, systematic evidence synthesis, and payer communication strategies for niche immunology indications.

9. Cytel

Cytel combines statistical innovation with HEOR methodology to support evidence generation for immunology brands. Their expertise in adaptive trial design, Bayesian statistics, and NMA provides scientifically rigorous inputs for economic models used in HTA and reimbursement submissions.

10. Precision HEOR

Precision HEOR is a boutique consultancy delivering high-quality outcomes research and value communication strategies. They work closely with immunology brand teams to develop evidence plans, global value dossiers, and payer-facing materials that articulate the clinical and economic value of treatments for autoimmune diseases.

Conclusion

As the immunology and autoimmune diseases market continues to expand driven by a robust pipeline of biologics, JAK inhibitors, and cell therapies the role of HEOR has never been more critical. From cost-effectiveness models to real-world evidence strategies, the companies listed above represent the leading HEOR Analysis Firms equipped to help pharmaceutical manufacturers demonstrate value, achieve market access, and improve patient outcomes.

Among all these players, DelveInsight continues to lead with its specialized focus, end-to-end HEOR capabilities, and deep immunology expertise making it the go-to partner for companies navigating the complex payer and HTA landscape in autoimmune disease.